echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Announcement of the State Food and Drug Administration on Suspension of Import, Sale and Use of Belgian UCB Pharma SA Levetiracetam Concentrated Solution for Injection

    Announcement of the State Food and Drug Administration on Suspension of Import, Sale and Use of Belgian UCB Pharma SA Levetiracetam Concentrated Solution for Injection

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the State Food and Drug Administration organized an overseas off-site inspection of UCB Pharma SA in Belgium, and the inspected product was levetiracetam injection concentrated solution (Import Registration No.
    : H20170341, specification 5 ml: 500 mg, trade name Kaipu orchid)
    .
    The inspection found that the validity period of some batches of products of this variety was inconsistent with the validity period of registration approval.
    The inspection concluded that the production of this variety did not meet the requirements of China's "Good Manufacturing Practice for Drugs (Revised in 2010)"
    .
    In order to ensure the safety of public medication, in accordance with the relevant provisions of the Drug Administration Law of the People's Republic of China, the State Food and Drug Administration has decided to suspend the import, sale and use of this product in China from now on, and investigate and deal with relevant issues in accordance with the law
    .
    The drug supervision and administration departments of all import ports suspend the issuance of import customs clearance certificates for this product
    .
    Hereby announce
    .
    State Food and Drug Administration August 22, 2022
    Recently, the State Food and Drug Administration organized an overseas off-site inspection of UCB Pharma SA in Belgium, and the inspected product was levetiracetam injection concentrated solution (Import Registration No.
    : H20170341, specification 5 ml: 500 mg, trade name Kaipu orchid)
    .
    The inspection found that the validity period of some batches of products of this variety was inconsistent with the validity period of registration approval.
    The inspection concluded that the production of this variety did not meet the requirements of China's "Good Manufacturing Practice for Drugs (Revised in 2010)"
    .
    In order to ensure the safety of public medication, in accordance with the relevant provisions of the Drug Administration Law of the People's Republic of China, the State Food and Drug Administration has decided to suspend the import, sale and use of this product in China from now on, and investigate and deal with relevant issues in accordance with the law
    .
    The drug supervision and administration departments of all import ports suspend the issuance of import customs clearance certificates for this product
    .
    Hereby announce
    .
    State Food and Drug Administration August 22, 2022
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.